In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]
Normally I don't write about pre-clinical things unless they are particularly interesting. You guessed it; I found a preclinical item that is interesting. According to a recent published study by Richard Pestell, M.D., Ph.D., MBA, Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University the receptor CCR5, which is targeted by already approved [...]
Bayer Healthcare has announced that they will be resuming production of Xofigo® (radium Ra 223 dichloride) for new patients beginning on Monday, November 17th. Xofigo is the newly FDA approved radiopharmaceutical treatment for men with castrate resistant metastatic prostate cancer (mCRPC) with bone metastases without any known visceral metastases. On October 8, 2014 Bayer informed [...]
Bayer HealthCare has announced that they have now resumed production of Xofigo (Ra 223 dichloride). Bayer has indicated that an initial lot of Xofigo has already been released so some patients will be able to re-start their treatment as early as this week. Bayer is in the process of contacting treating physicians with the news. [...]
The world wide supply of Xofigo (radium Ra-223 dichloride) available for patients will run out on October 10, 2014. Xofigo is the newly FDA approved treatment for men with castrate resistant metastatic prostate cancer (CRPC) with bone metastases without any known visceral metastases. Individual batches of drugs are inspected prior to release to patients. Bayer’s [...]
A man in the advanced prostate cancer online support group has asked, “Why the radiation (external beam to relieve bone pain from prostate cancer and to protect the bones from fractures) is given in so many "mini" doses rather than one or two larger doses. The answer is it doesn't necessarily have to be delivered [...]
Somehow I have been negligent and not let people know that I have written and posted a major update of my “Guide to Advanced Prostate Cancer.” As in the past, it is available as a free download from the Malecare web site. Helping me to update the book was prostate cancer survivor Craig Pynn and [...]
I really thought we had gotten over this problem, but an article appearing in a recent report in the Journal of Clinical Oncology indicates that the age old problem that often our doctors fail to supply adequate pain medications to advanced cancer survivors because a fear of drug addiction This attitude still hampers good survivorship [...]
The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting framework of our bodies. Like the rest of us bones are constructed of cells. These cells compose a network or [...]
I have written a lot about how we need more data about the many new drugs we have to treat men with advanced prostate cancer. The many questions that continue to swirl around us pertain to the development of cross resistance (taking one drug causes another to not work) between these new drugs, knowing the [...]
